Skip to main content
. 2023 Jun 30;12(13):4414. doi: 10.3390/jcm12134414

Figure 3.

Figure 3

Quality control data from the MSC manufacturing process. (Aa) Immunophenotype analysis at the end of P3 after continuous (n = 7) and discontinuous (n = 13) MSC production. Data represent the mean ± SD. (Ab) Immunomodulation capacity of MSCs at P3 between continuous (n = 5) and discontinuous (n = 2) MSC production. (Ac) The clonogenic capacity was evaluated by the colony-forming-unit fibroblast (CFU-F) assay at the end of P3 after continuous (n = 7) and discontinuous (n = 13) MSC production. (Ad) A paired analysis was also performed between continuous P3 (n = 5) and discontinuous P3 (n = 13) production starting from the same P2 (* p < 0.05, CP P3 vs. DP P3). (Ae) Safety controls were performed at the end of P3 after continuous (n = 7) and discontinuous (n = 13) MSC production. (Af,Ag) Osteogenic and adipogenic differentiation capacities were evaluated at the end of P3 after continuous (Af) and discontinuous (Ag) MSC production by the revelation of calcium deposits and lipid vesicles, respectively. (Ba) Viability after thawing continuous (n = 16) and discontinuous (n = 42) MSC production. (Bb) The clonogenic capacity evaluated by the CFU-F assay after thawing continuous (n = 4) and discontinuous (n = 19) MSC production. (P2: passage 2, CP P3: continuous passage 3, DP P3: discontinuous passage 3, ns: not significant). One color symbol corresponds to one umbilical cord.